A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. 2021

Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

OBJECTIVE Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports. We performed a nationwide study to estimate the incidence and impact of inpatient opportunistic infections. METHODS The incidence rate (IR) and incidence rate ratio (IRR) for Swedish CLL patients diagnosed 1994-2013, and matched controls were calculated, as well as the case-fatality ratio (CFR). RESULTS Among 8989 CLL patients, a total of 829 opportunistic infections were registered (IR 16.6 per 1000 person-years) compared with 252 opportunistic infections in 34 283 matched controls (IR 0.99). The highest incidence in the CLL cohort was for Pneumocystis pneumonia (200 infections, IR 4.03); Herpes zoster (146 infections, IR 2.94), and Pseudomonas (83 infections, IR 1.66) infections. The highest risk relative to matched controls was observed for Pneumocystis pneumonia (IRR 114, 95% confidence interval 58.7-252). The 60-day CFR for CLL patients with opportunistic infections was 23% (188/821), highest for progressive multifocal encephalopathy (5/7, 71%) and aspergillosis (25/60, 42%). CONCLUSIONS We have uniquely depicted the incidence of rare and serious infections in CLL patients and found a relatively high incidence of Pneumocystis pneumonia. Of the most common opportunistic infections, CLL patients with aspergillosis had the poorest prognosis.

UI MeSH Term Description Entries
D007297 Inpatients Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment. Inpatient
D008297 Male Males
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D010880 Piperidines A family of hexahydropyridines.
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
November 1979, Southern medical journal,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
March 2023, Leukemia & lymphoma,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
April 1992, American journal of hematology,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
June 2018, Medecine et maladies infectieuses,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
February 2016, Blood,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
April 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
October 2020, Leukemia & lymphoma,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
April 2016, The New England journal of medicine,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
April 2016, The New England journal of medicine,
Vilhjálmur Steingrímsson, and Gauti Kjartan Gíslason, and Sigrún Þorsteinsdóttir, and Saemundur Rögnvaldsson, and Magnús Gottfreðsson, and Thor Aspelund, and Ingemar Turesson, and Magnus Björkholm, and Ola Landgren, and Sigurdur Y Kristinsson
April 2016, The New England journal of medicine,
Copied contents to your clipboard!